Updated:
BioVaxys Technology Corp.
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company focused on out-licensing immunotherapy assets developed from its proprietary DPX™...
BioVaxys Technology Corp.
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company focused on out-licensing immunotherapy assets developed from its proprietary DPX™ platform. The DPX platform is a lipid-in-oil formulation that enables sustained, targeted immune responses and has demonstrated safety and efficacy in multiple Phase 1 and Phase 2B clinical studies across oncology, infectious disease, allergy, and autoimmune disorders. The company's lead clinical asset, Maveropepimut-S (MVP-S), has shown a 21% overall response rate and 63% disease control rate in recurrent ovarian cancer.
General information
Firm type
other
Location
City
New York
Sector focus
Frequently asked questions
What investment stages or instruments does BioVaxys use to raise capital?
BioVaxys raises funding through public equity offerings, warrants, private placements, and grants. It does not operate fund vehicles, make direct investments in other companies, or engage in co-investment structures.
Who leads investment decisions at BioVaxys?
BioVaxys is led by its management team and board of directors, typical of a publicly traded biotech. Specific named individuals and their roles should be referenced from the firm's own filings and public communications, as those details evolve with corporate governance changes.
What are the main therapeutic areas for BioVaxys?
BioVaxys' pipeline includes a COVID-19 booster vaccine candidate (BVX-0320) and immunotherapies for ovarian cancer and other cancers. The firm also explores early-stage research in other infectious diseases and oncology indications.
Has BioVaxys received any regulatory approvals or generated revenue from product sales?
As of 2025, per public filings, BioVaxys has not received marketing approval for any product candidate and has not generated revenue from product sales. It is a clinical-stage biotechnology company with no approved therapies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: